Overview of current policy for rare disease in China
2018 was regarded as a milestone of rare disease management in China as, for the first time after decades of negligence in this area, China published the First List of Rare Diseases (FLRDs). This was a key step in improving and standardising the regulatory system of rare disease management, orphan drug development, and review and approval.
In this FLRDs, 121 diseases were included and officially defined as rare diseases. Since then, a series of regulations and policies have been released and implemented to support the development of rare disease treatment and management.
Several key trends on the current policy and market dynamics for rare disease in China are outlined in this paper. With strong expertise and deep understanding of the rare disease field in China, Deallus is well-positioned to support Pharma to fully understand the current landscape and maximise success in the market.
Download to read more.
You may also be interested in…
World Kidney Cancer Day: The future of RCC treatment
World Kidney Cancer Day brings much needed attention to a disease affecting hundreds of thousands of people worldwide.
Revolutionizing Blood Cancer Treatment: A Dive into Cutting-Edge Therapies
World Blood Cancer Day [28 May 2024] serves as a stark reminder of the significant challenges faced by the millions battling these life-threatening diseases. Here at Deallus, we have been privileged enough to partner with many leading companies in this space to support the development of lifechanging therapies across haemato-oncology.
World Day for Cultural Diversity 2024
Feel the driving force of Cultural Diversity as voiced by my global Deallus colleagues. Happy World Day of Cultural Diversity!
The need for innovation in Women’s Health
Women’s Health Week (14-20 May 2024) provides an opportunity to reflect on the changing landscape for the access, treatment, and representation of women across healthcare. We’re proud that many of the clients we are partnering with are part of driving much needed change and reform within Women’s Health, lending our experience and expertise to the innovation that is required.